查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1983708

免疫腫瘤市場：依治療方法、適應症、治療階段和最終用戶分類－2026-2032年全球市場預測

Immuno-Oncology Market by Therapy Type, Indication, Line Of Therapy, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，免疫腫瘤學市場價值將達到 64.9 億美元，到 2026 年將成長至 71.6 億美元，到 2032 年將達到 129.1 億美元，複合年成長率為 10.30%。

主要市場統計數據
基準年 2025 64.9億美元
預計年份：2026年 71.6億美元
預測年份：2032年 129.1億美元
複合年成長率 (%) 10.30%

本書整合了治療方法、適應症和醫療保健服務的趨勢，為不斷演變的免疫腫瘤學領域的高級決策者提供了策略指南。

免疫腫瘤學的發展趨勢正在重塑腫瘤學實踐，透過機制上的突破性進展和新的治療模式，改變臨床醫生、保險公司和研發人員應對癌症治療的方式。本執行摘要整合了橫斷面趨勢、細分市場洞察、監管和政策促進因素以及可操作的建議，旨在為生物製藥、臨床研究和醫療服務領域的高級決策者提供有價值的資訊。

對重塑免疫腫瘤學發展和商業化的科學、製造、監管和市場進入因素進行全面分析。

由於科學、技術和商業性因素的融合，免疫腫瘤學領域正經歷著變革性的轉變，這些因素正在重塑競爭格局和病患治療管道。細胞工程、新一代查核點調控、抗原鑑定和生產規模化的進步，使得更精準、更持久、更具聯合療效的治療性介入成為可能。因此，治療策略正從單一療法轉向整合療法，將查核點抑制劑與疫苗、過繼性細胞療法、細胞激素調控或溶瘤平台結合，以增強抗腫瘤反應。

美國累積關稅措施對免疫腫瘤學供應鏈、製造地和臨床開發營運的策略影響。

關稅的徵收和貿易政策的變化正對免疫腫瘤領域的全球供應鏈和成本結構產生重大影響，尤其是在依賴跨境採購試劑、專用設備和契約製造的先進治療方法。關稅的累積趨勢會影響企業生產基地的選址、供應商網路的建構方式，以及承銷商和投資者為生產計分類配的風險溢價。對於需要複雜低溫運輸物流和一次性耗材的治療方法，例如細胞療法和DNA疫苗，關稅導致的成本增加會對採購、批次放行計畫和最終治療定價產生連鎖反應。

將治療方法、臨床適應症、臨床環境和作用機制連結起來的詳細細分分析，可指導產品組合優先排序和市場進入計劃。

細分市場洞察揭示了每種治療方法類型、適應症、最終用戶、治療線和作用機制的差異化競爭和證據需求。就治療方法類型而言，癌症疫苗、細胞療法、查核點抑制劑、細胞激素和溶瘤病毒各自遵循不同的研發路徑。在癌症疫苗中，樹突細胞疫苗、DNA疫苗和胜肽疫苗在個人化需求、生產複雜性和給藥方法方面存在差異，這些差異會影響臨床實驗室設計和商業化策略。細胞療法包括CAR-T療法、NK細胞療法和TCR-T療法。隨著CAR-T療法細分為異體移植和自體移植，經營模式也隨之分化。自體移植強調患者個體化的物流和臨床調整，而異體移植則優先考慮規模化、庫存管理和現貨產品的供應。

對美洲、歐洲、中東、非洲和亞太市場的法規、報銷、臨床試驗和生產製造進行區域策略洞察。

區域趨勢正在影響美洲、歐洲、中東和非洲以及亞太地區的監管管道、報銷框架、臨床試驗受試者招募和製造地選擇。在美洲，完善的法規結構和高密度的三級醫療中心支持了先進免疫療法的快速普及，而商業化策略必須應對複雜的支付方環境，該環境強調價值驗證和基於結果的合約。該地區的臨床生態系統能夠支持大規模臨床試驗，並促進產業界、學術機構和契約製造組織 (CMO) 之間的合作，從而支持有前景的候選藥物的快速迭代開發和規模化生產。

本文檔展示了企業級競爭與合作策略，說明了創新公司和服務供應商如何在先進免疫腫瘤學領域取得突破。

免疫腫瘤學領域的關鍵公司層面趨勢反映了創新者、成熟的腫瘤企業和專業契約製造服務供應商等不同企業所採取的多元化策略。領先的研發公司透過專有平台、聯合治療策略以及從早期發現到後期檢驗的整合式臨床開發專案來脫穎而出。對於專注於細胞療法的公司而言，投資於生產控制、療效評估和供應夥伴關係對於加快產品上市速度和確保產品品質的穩定性至關重要。疫苗研發公司則優先考慮抗原發現、遞送最佳化以及與伴隨診斷的整合，以提高反應的可預測性。

經營團隊採用的實用策略建議，旨在使科學創新與可製造性、償還能力以及彈性供應鏈的實施保持一致。

產業領導者應採取一系列綜合策略措施，在管控臨床、營運和商業性風險的同時，加速專案成功。首先，應在研發早期階段優先考慮平台的可擴展性和可製造性，以避免價值鏈後期出現代價高昂的重新設計。這包括投資於標準化的療效測試、模組化的生產流程以及供應商多元化，以支持自體和異體性管道。其次，臨床開發應與支付方的預期保持一致，並透過將比較性終點、健康經濟學數據收集和真實世界數據（RWE）生成整合到關鍵項目中，促進產品上市後的報銷談判。

一種穩健的基於三角測量的調查方法，結合了關鍵相關人員的見解、透過二手文獻進行的檢驗以及基於情境的供應鏈和政策分析。

本研究採用三角測量調查方法進行綜合分析，該方法結合了對關鍵相關人員的訪談、對二手文獻的分析以及透過用例和監管文件審查進行的交叉檢驗。為了了解實際情況、證據預期和推廣障礙，我們對臨床研究人員、生產專家、監管事務專業人員、支付方和醫院藥物採納決策者進行結構化訪談，並將訪談作為主要資訊資訊來源。二級資訊來源包括同行評審的科學文獻、監管指導文件和企業資訊披露，以檢驗機制趨勢、臨床結果和技術進步。

將免疫腫瘤學領域的創新轉化為永續的臨床和商業性影響，需要將策略挑戰和營運重點進行簡潔的整合。

總之，免疫腫瘤學正處於一個轉折點，科學知識、生產創新、政策趨勢和商業策略在此交匯，共同決定哪些治療方法能為患者帶來持久的益處。從癌症疫苗和細胞激素到細胞療法和查核點抑制劑，種類繁多的治療方法既帶來了複雜性，也帶來了機會。要成功地將創新應用於臨床實踐，需要儘早將研發目標與可生產性、監管策略以及以支付方為中心的證據產生結合。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：免疫腫瘤市場：依治療方法分類

  • 癌症疫苗
  • 細胞療法
    • CAR-T療法
      • 同種
      • 自有住房
    • NK細胞療法
    • TCR-T療法
  • 查核點抑制劑
    • CTLA-4抑制劑
    • PD-1抑制劑
    • PD-L1抑制劑
  • 細胞激素
  • 溶瘤病毒

第9章：免疫腫瘤市場：依適應症分類

  • 乳癌
    • HER2陽性乳癌
    • 三陰性乳癌
  • 結腸癌
  • 肺癌
    • 非小細胞肺癌
    • 小細胞肺癌
  • 淋巴瘤
  • 黑色素瘤
    • 皮膚黑色素瘤
    • 葡萄膜黑色素瘤

第10章：免疫腫瘤市場：依治療階段分類

  • 第 1 行
  • 從第四行開始
  • 第二行
  • 第三行

第11章：免疫腫瘤市場：依最終用戶分類

  • 學術機構
  • 癌症研究機構
  • 診所
  • 醫院

第12章：免疫腫瘤市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：免疫腫瘤市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 免疫腫瘤市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國免疫腫瘤市場

第16章：中國免疫腫瘤市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Agenus Inc.
  • Allogene Therapeutics, Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Autolus Limited
  • BeiGene, Ltd.
  • BioNTech SE
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Immutep Ltd.
  • Johnson & Johnson
  • Juno Therapeutics, Inc.
  • Legend BIoTech Corporation
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-FF012EDC38BF

The Immuno-Oncology Market was valued at USD 6.49 billion in 2025 and is projected to grow to USD 7.16 billion in 2026, with a CAGR of 10.30%, reaching USD 12.91 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.49 billion
Estimated Year [2026] USD 7.16 billion
Forecast Year [2032] USD 12.91 billion
CAGR (%) 10.30%

Strategic orientation to the evolving immuno-oncology landscape integrating therapeutic modalities, indications, and care delivery dynamics for senior decision-makers

The immuno-oncology landscape continues to redefine oncology practice through mechanistic breakthroughs and new therapeutic paradigms that shift how clinicians, payers, and developers approach cancer treatment. This executive summary synthesizes cross-cutting trends, segmentation intelligence, regulatory and policy drivers, and actionable recommendations to inform senior decision-makers across biopharma, clinical research, and healthcare delivery organizations.

Over the past decade, immuno-oncology matured from proof-of-concept studies to mainstream standards of care for several indications, and the field now spans a wide range of modalities. Based on therapy type, the space comprises cancer vaccines, cell therapy, checkpoint inhibitors, cytokines, and oncolytic viruses. Within cancer vaccines, dendritic cell vaccines, DNA vaccines, and peptide vaccines each represent distinct development pathways and manufacturing requirements. Cell therapy includes CAR-T therapy, NK cell therapy, and TCR-T therapy, with CAR-T further divided into allogeneic and autologous approaches. Checkpoint inhibitors encompass CTLA-4 inhibitors, PD-1 inhibitors, and PD-L1 inhibitors, which continue to evolve through combination regimens and novel formats.

Indication-driven dynamics shape both clinical development priorities and commercial access strategies. The market spans breast cancer, colorectal cancer, lung cancer, lymphoma, and melanoma, with notable subsegments such as Her2-positive and triple-negative breast cancer, non-small cell lung cancer and small cell lung cancer, and cutaneous and uveal melanoma. End users range from academic institutes and cancer research institutes to clinics and hospitals, reflecting both centralized and decentralized models of care delivery. Line-of-therapy considerations span first line through fourth line or beyond, while mechanistic distinctions separate active immunotherapy from passive approaches; active immunotherapy includes cancer vaccines and cytokine-based therapies, and passive immunotherapy includes adoptive cell transfer, checkpoint inhibitors, and monoclonal antibodies, with adoptive cell transfer comprising CAR-T and TCR-T therapies.

This introduction frames the deeper insights that follow, highlighting the interplay between therapeutic innovation, regulatory pressures, reimbursement realities, and shifting supply chains. It is intended to equip executives with a clear orientation to the strategic levers that will determine competitive positioning and clinical impact over the coming years.

Comprehensive analysis of scientific, manufacturing, regulatory, and market-access forces that are reshaping immuno-oncology development and commercialization

The immuno-oncology sector is experiencing transformative shifts driven by converging scientific, technological, and commercial forces that are reshaping competition and patient pathways. Advances in cellular engineering, next-generation checkpoint modulation, antigen identification, and manufacturing scalability are enabling more precise, durable, and combinable interventions. As a result, therapeutic strategies are migrating from single-agent approaches to integrated regimens that pair checkpoint inhibitors with vaccines, adoptive cell therapies, cytokine modulation, or oncolytic platforms to amplify antitumor responses.

Concurrently, innovation in cell therapy formats-spanning autologous CAR-T constructs to off-the-shelf allogeneic CAR-T and NK cell therapies-reduces time-to-treatment and expands access beyond tertiary centers. The maturation of CAR-T and TCR-T research underscores an increasing focus on manufacturability, standardized potency assays, and closed-system production to support scale-up. At the same time, cancer vaccines are regaining traction as neoantigen discovery improves and DNA and peptide platforms become more adaptable to personalized approaches. Checkpoint inhibitor strategies are moving beyond broad PD-1/PD-L1 blockade to exploit combinatorial biology and bispecific constructs that modulate multiple immune axes.

Regulatory ecosystems and payer frameworks are also adapting to these innovations. Accelerated approval pathways and conditional reimbursement arrangements are being used to reconcile early clinical benefit with longer-term evidence generation, and value-based contracting is increasingly applied to high-cost cell and gene therapies. This shift demands more robust real-world evidence capabilities and post-market surveillance infrastructures. Supply chain resilience has risen on the executive agenda, particularly as advanced therapies depend on cold chain logistics, single-use components, and specialized manufacturing capabilities. Geopolitical factors and trade policies are introducing further complexity into sourcing and cross-border distribution.

Taken together, these transformative shifts require an integrated response that combines scientific rigor with commercial pragmatism. Organizations that align discovery priorities with pragmatic considerations-such as scalable manufacturing, differentiated clinical positioning, and adaptive reimbursement strategies-are better positioned to translate scientific breakthroughs into sustainable clinical impact and commercial success.

Strategic implications of cumulative United States tariff policy on immuno-oncology supply chains, manufacturing locations, and clinical development operations

The imposition of tariffs and trade policy changes has material implications for global supply chains and cost structures in immuno-oncology, particularly for advanced therapies that rely on cross-border sourcing of reagents, specialized equipment, and contract manufacturing capabilities. Cumulative tariff dynamics influence where organizations choose to locate production, how they structure supplier networks, and the risk premiums that underwriters and investors assign to manufacturing projects. For therapies such as cell therapy and DNA-based vaccines that require complex cold chain logistics and single-use materials, tariff-induced cost increases can cascade across procurement, batch release timelines, and final therapy pricing.

Manufacturers are responding through a mix of tactical and strategic actions. Tactical measures include re-negotiation of supplier contracts, hedging of foreign exchange exposures, and re-routing of logistics to minimize tariff exposure. Strategic responses emphasize regionalization of manufacturing capabilities, nearshoring of critical component production, and investments in modular, mobile, or decentralized manufacturing facilities that reduce cross-border movement of high-value biologicals. These strategic moves are often accompanied by tighter supplier qualification processes and a higher emphasis on dual sourcing for critical inputs to reduce single-point-of-failure risks.

Clinical trial operations are also affected as tariffs can increase the cost of investigational product distribution and device imports required for complex protocols. Sponsors are increasingly evaluating alternative trial designs and decentralized approaches to reduce the need for physical shipping of intermediate products across borders. In parallel, regulatory authorities may require additional quality and provenance documentation for products moved across tariff-impacted supply chains, increasing the administrative burden on sponsors and contract manufacturers.

In summary, cumulative tariff pressures accelerate the trend toward supply chain resilience and regional production capacity, and they elevate the importance of strategic procurement, flexible manufacturing architectures, and regulatory engagement. Organizations that proactively redesign their supply networks and incorporate tariff scenarios into long-range planning will mitigate operational disruption and preserve competitive flexibility.

In-depth segmentation intelligence linking therapeutic modalities, clinical indications, care settings, and mechanisms to guide portfolio prioritization and market access planning

Segmentation insights reveal differentiated competitive dynamics and evidence needs across therapy types, indications, end users, lines of therapy, and mechanisms of action. By therapy type, cancer vaccines, cell therapy, checkpoint inhibitors, cytokines, and oncolytic viruses each present distinct development pathways. Within cancer vaccines, dendritic cell vaccines, DNA vaccines, and peptide vaccines vary in personalization requirements, manufacturing complexity, and delivery modalities, which influence clinical trial designs and commercialization strategies. Cell therapy encompasses CAR-T therapy, NK cell therapy, and TCR-T therapy, and the split of CAR-T into allogeneic and autologous approaches creates divergent business models: autologous therapies emphasize patient-specific logistics and clinical coordination, while allogeneic therapies prioritize scale, inventory management, and off-the-shelf availability.

Indication-specific segmentation further refines opportunity and risk. Breast cancer, colorectal cancer, lung cancer, lymphoma, and melanoma have unique tumor microenvironments, prior therapy landscapes, and biomarker frameworks. Subsegments such as Her2-positive and triple-negative breast cancer, non-small cell lung cancer and small cell lung cancer, and cutaneous and uveal melanoma each require tailored development strategies, with different expectations for combination regimens and endpoints. End users-academic institutes, cancer research institutes, clinics, and hospitals-differ in their capacity to deliver complex immunotherapies, with tertiary cancer centers typically leading in adoption of cell therapies while community hospitals and clinics increasingly provide checkpoint inhibitor administration and vaccine-based interventions.

Line-of-therapy considerations are critical for positioning and value communication. First-line indications often demand robust comparative evidence and alignment with standard-of-care protocols, whereas later-line settings can accommodate accelerated pathways and biomarker-driven niche approvals. Mechanistic segmentation distinguishes active immunotherapy, which includes cancer vaccines and cytokine-based therapies, from passive immunotherapy, which comprises adoptive cell transfer, checkpoint inhibitors, and monoclonal antibodies. Within passive immunotherapy, adoptive cell transfer-encompassing CAR-T and TCR-T therapies-commands particular attention for its clinical complexity and potential curative outcomes in select populations.

Taken together, segmentation insights suggest that commercial success depends on aligning modality-specific strengths with indication-specific needs, optimizing delivery models for distinct end-user settings, and sequencing evidence generation to match line-of-therapy expectations. Organizations that integrate these segmentation layers into portfolio planning and market access strategies will increase the precision of their clinical pathways and the clarity of their value propositions.

Regional strategic insights on regulatory, reimbursement, clinical trial, and manufacturing considerations across Americas, EMEA, and Asia-Pacific markets

Regional dynamics shape regulatory pathways, reimbursement paradigms, clinical trial recruitment, and manufacturing footprint decisions across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, established regulatory frameworks and a high concentration of tertiary care centers support rapid adoption of advanced immunotherapies, while commercialization strategies must navigate complex payer landscapes that emphasize value demonstration and outcomes-based contracting. Clinical ecosystems in this region enable large-scale trials and facilitate collaborations between industry, academic centers, and contract manufacturing organizations, which supports rapid iteration and scale-up for successful candidates.

Europe, Middle East & Africa presents a heterogeneous regulatory and reimbursement environment where regional agencies and national health systems influence market entry timing and pricing strategies. Centralized approvals can accelerate cross-border access within parts of Europe, but differential national reimbursement decisions and HTA requirements necessitate tailored evidence packages and credentialing initiatives. Stakeholders in this region increasingly focus on cost-effectiveness and real-world data to support access, and partnerships with regional manufacturing hubs can mitigate supply chain complexity.

Asia-Pacific reflects an expanding capacity for clinical development and manufacturing, with several markets prioritizing domestic biopharmaceutical innovation and regulatory modernization. Fast-growing trial populations, diversified payer models, and evolving regulatory pathways create opportunities for both multinational collaboration and local development. However, differences in standard-of-care, biomarker prevalence, and delivery infrastructure require nuanced market entry approaches. In response, companies are investing in regional manufacturing and distribution capabilities, local clinical partnerships, and market-specific evidence generation strategies to accelerate adoption while managing commercial risk.

Across regions, a common imperative is to align clinical development, regulatory engagement, and commercial planning with local health system realities. Firms that proactively design regional strategies-balancing centralized capabilities with localized execution-will better navigate heterogenous approval processes, reimbursement expectations, and patient access pathways.

Company-level competitive dynamics and partnership strategies demonstrating how innovators and service providers are enabling advanced immuno-oncology breakthroughs

Key company-level dynamics in immuno-oncology reflect diverse strategic approaches across innovators, established oncology franchises, and specialized contract manufacturing and service providers. Leading developers are differentiating through proprietary platforms, combination strategies, and integrated clinical development programs that span early discovery to late-stage validation. For companies focused on cell therapy, investments in manufacturing controls, potency assays, and supply chain partnerships are central to reducing time-to-patient and ensuring consistent product quality. Vaccine developers are prioritizing antigen discovery, delivery optimization, and companion diagnostic linkages to enhance response predictability.

Competitive positioning increasingly depends on collaborative networks and externalization of capabilities. Strategic partnerships between biotech innovators and larger oncology companies facilitate access to commercialization expertise, global distribution channels, and payer engagement resources. In parallel, alliances with academic institutions and cancer research institutes underpin translational research and rapid patient recruitment. Contract manufacturing organizations and technology providers that offer scalable, validated platforms for viral vectors, cell culture, and nucleic acid production are gaining importance as critical enablers of program advancement.

Corporate strategies also vary by risk appetite and portfolio breadth. Some companies pursue high-risk, high-reward assets with potentially transformative clinical profiles, while others focus on incremental improvements to existing standards of care to capture early market share and payer acceptance. Across these approaches, executive teams emphasize robust clinical operational capabilities, regulatory intelligence, and commercialization planning to bridge the gap between clinical proof and patient impact.

Ultimately, companies that combine deep scientific differentiation with pragmatic operational execution-investing in manufacturing resilience, regulatory dialogue, and payer-aligned evidence generation-are best placed to convert innovation into sustainable clinical and commercial outcomes.

Actionable strategic recommendations for leadership teams to align scientific innovation with manufacturability, reimbursement readiness, and resilient supply chain execution

Industry leaders should pursue an integrated set of strategic actions to accelerate program success while managing clinical, operational, and commercial risk. First, prioritize platform scalability and manufacturability during early development to avoid costly redesigns later in the value chain. This entails investing in standardized potency assays, modular manufacturing workflows, and supplier diversification to support both autologous and allogeneic pathways. Second, align clinical development with payer expectations by embedding comparative endpoints, health economics data collection, and real-world evidence generation into pivotal programs to streamline reimbursement conversations from launch.

Third, develop regionally nuanced market access strategies that reflect local regulatory requirements, HTA criteria, and delivery infrastructure. This requires early regulatory engagement, targeted evidence packages for different markets, and partnerships with regional clinical sites to ensure rapid adoption. Fourth, embrace combination-development frameworks that strategically pair checkpoint inhibitors, vaccines, cytokines, or cell therapies to address resistant tumor microenvironments; such programs should include biomarker-driven patient selection and adaptive trial designs to optimize signal detection.

Fifth, strengthen supply chain resilience through nearshoring options, dual sourcing of critical materials, and investments in cold chain and logistics capabilities to mitigate tariff and trade-related interruptions. Sixth, cultivate cross-sector partnerships with academic centers, technology platforms, and contract manufacturers to accelerate translational work and de-risk operational execution. Finally, ensure leadership teams integrate commercial planning early in development to harmonize clinical, regulatory, manufacturing, and market access strategies, thereby shortening time-to-value and improving patient reach.

Taken together, these recommendations form a cohesive blueprint for executives seeking to translate scientific innovation into durable clinical impact and commercial success while navigating an increasingly complex policy and operational environment.

Robust triangulated research methodology combining primary stakeholder insights, secondary literature validation, and scenario-based supply chain and policy analysis

This research synthesis draws on a triangulated methodology combining primary stakeholder interviews, secondary literature analysis, and cross-validation through case studies and regulatory document reviews. Primary inputs included structured interviews with clinical investigators, manufacturing experts, regulatory affairs professionals, payers, and hospital formulary decision-makers to capture operational realities, evidence expectations, and adoption barriers. Secondary sources encompassed peer-reviewed scientific literature, regulatory guidance documents, and company disclosures to validate mechanistic trends, clinical outcomes, and technology trajectories.

Analytical frameworks used in the research included segmentation by therapy type, indication, end user, line of therapy, and mechanism to map distinct evidence pathways and commercialization challenges. Scenario analyses examined the operational impact of tariff changes, supply chain disruption, and regional manufacturing shifts. Competitive landscaping incorporated public filings, clinical trial registries, and patent landscaping to assess differentiation at the platform level. Where appropriate, case studies of recent approvals and commercialization rollouts were used to illustrate translational best practices and pitfalls.

The approach emphasizes transparency and reproducibility: assumptions, data sources, and analytical choices were documented to facilitate client-driven sensitivity testing and bespoke adaptation. Limitations include the dynamic nature of regulatory and trade policy environments, which require ongoing monitoring, and the variability in local healthcare infrastructures that can affect transferability of specific operational models. Nevertheless, the methodology provides a robust foundation for strategic decision-making and can be extended through commissioned bespoke analyses focused on specific modalities, regions, or commercial scenarios.

Concise synthesis of strategic imperatives and operational priorities to convert immuno-oncology innovation into sustainable clinical and commercial impact

In conclusion, immuno-oncology is at an inflection point where scientific capability, manufacturing innovation, policy dynamics, and commercial strategy converge to determine which therapies will achieve durable patient impact. The diversity of modalities-from cancer vaccines and cytokines to cell therapies and checkpoint inhibitors-creates both complexity and opportunity. Successful translation of innovation into care requires early alignment of development objectives with manufacturability, regulatory strategy, and payer-focused evidence generation.

Organizations that proactively address supply chain resilience, regional regulatory heterogeneity, and the evolving expectations of payers and providers will be best positioned to scale transformative therapies. By integrating the segmentation, regional, and company-level insights presented here, executives can prioritize investments that maximize clinical benefit while managing operational risk. The recommendations provided offer a pragmatic roadmap to guide portfolio decisions and commercialization planning as the field continues to evolve.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Immuno-Oncology Market, by Therapy Type

  • 8.1. Cancer Vaccines
  • 8.2. Cell Therapy
    • 8.2.1. CAR-T Therapy
      • 8.2.1.1. Allogeneic
      • 8.2.1.2. Autologous
    • 8.2.2. NK Cell Therapy
    • 8.2.3. TCR-T Therapy
  • 8.3. Checkpoint Inhibitors
    • 8.3.1. CTLA-4 Inhibitors
    • 8.3.2. PD-1 Inhibitors
    • 8.3.3. PD-L1 Inhibitors
  • 8.4. Cytokines
  • 8.5. Oncolytic Viruses

9. Immuno-Oncology Market, by Indication

  • 9.1. Breast Cancer
    • 9.1.1. Her2-Positive Breast Cancer
    • 9.1.2. Triple-Negative Breast Cancer
  • 9.2. Colorectal Cancer
  • 9.3. Lung Cancer
    • 9.3.1. Nsclc
    • 9.3.2. Small Cell Lung Cancer
  • 9.4. Lymphoma
  • 9.5. Melanoma
    • 9.5.1. Cutaneous Melanoma
    • 9.5.2. Uveal Melanoma

10. Immuno-Oncology Market, by Line Of Therapy

  • 10.1. First Line
  • 10.2. Fourth Line Or Beyond
  • 10.3. Second Line
  • 10.4. Third Line

11. Immuno-Oncology Market, by End User

  • 11.1. Academic Institutes
  • 11.2. Cancer Research Institutes
  • 11.3. Clinics
  • 11.4. Hospitals

12. Immuno-Oncology Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Immuno-Oncology Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Immuno-Oncology Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Immuno-Oncology Market

16. China Immuno-Oncology Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Agenus Inc.
  • 17.6. Allogene Therapeutics, Inc.
  • 17.7. Amgen Inc.
  • 17.8. AstraZeneca PLC
  • 17.9. Autolus Limited
  • 17.10. BeiGene, Ltd.
  • 17.11. BioNTech SE
  • 17.12. Bristol-Myers Squibb Company
  • 17.13. Celgene Corporation
  • 17.14. Eli Lilly and Company
  • 17.15. Gilead Sciences, Inc.
  • 17.16. GlaxoSmithKline plc
  • 17.17. Immutep Ltd.
  • 17.18. Johnson & Johnson
  • 17.19. Juno Therapeutics, Inc.
  • 17.20. Legend Biotech Corporation
  • 17.21. Merck & Co., Inc.
  • 17.22. Moderna, Inc.
  • 17.23. Novartis AG
  • 17.24. Pfizer Inc.
  • 17.25. Regeneron Pharmaceuticals, Inc.
  • 17.26. Roche Holding AG
  • 17.27. Sanofi S.A.
  • 17.28. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL IMMUNO-ONCOLOGY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL IMMUNO-ONCOLOGY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA IMMUNO-ONCOLOGY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY ALLOGENEIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY ALLOGENEIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY ALLOGENEIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY AUTOLOGOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY AUTOLOGOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY NK CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY NK CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY NK CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY TCR-T THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY TCR-T THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY TCR-T THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY PD-L1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY PD-L1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CYTOKINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CYTOKINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CYTOKINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY ONCOLYTIC VIRUSES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY ONCOLYTIC VIRUSES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY ONCOLYTIC VIRUSES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY HER2-POSITIVE BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY HER2-POSITIVE BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY HER2-POSITIVE BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY TRIPLE-NEGATIVE BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY TRIPLE-NEGATIVE BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY TRIPLE-NEGATIVE BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY NSCLC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY NSCLC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY NSCLC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY SMALL CELL LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY SMALL CELL LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY SMALL CELL LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CUTANEOUS MELANOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CUTANEOUS MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CUTANEOUS MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY UVEAL MELANOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY UVEAL MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY UVEAL MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY FOURTH LINE OR BEYOND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY FOURTH LINE OR BEYOND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY FOURTH LINE OR BEYOND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY THIRD LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY ACADEMIC INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY ACADEMIC INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. GCC IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. GCC IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. GCC IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 212. GCC IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 213. GCC IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 214. GCC IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 215. GCC IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 216. GCC IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 217. GCC IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 218. GCC IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 219. GCC IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. BRICS IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. G7 IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 243. G7 IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. G7 IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 245. G7 IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 246. G7 IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 247. G7 IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 248. G7 IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 249. G7 IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 250. G7 IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 251. G7 IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 252. G7 IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 253. NATO IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 254. NATO IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. NATO IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 256. NATO IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 257. NATO IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 258. NATO IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 259. NATO IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 260. NATO IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 261. NATO IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 262. NATO IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 263. NATO IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 264. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 266. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 267. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 273. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 276. CHINA IMMUNO-ONCOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 277. CHINA IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. CHINA IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 279. CHINA IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 280. CHINA IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 281. CHINA IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 282. CHINA IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 283. CHINA IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 284. CHINA IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 285. CHINA IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 286. CHINA IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)